Author:
Shah Bijal D.,Smith Nathaniel J.,Feng Chaoling,Jeyakumar Sushanth,Castaigne Jean-Gabriel,Faghmous Imi,Masouleh Behzad Kharabi,Malone Daniel C.,Bishop Michael R.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference43 articles.
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.
2. Spoorendonk J, Feng C, Shah D, et al. PCN183 global incidence, prevalence, and survival in relapsed/refractory (R/R) adult acute lymphoblastic leukemia (aALL): a systematic literature review (SLR). Value Health. 2020;23:S455.
3. National Cancer Institute. SEER Cancer Statistics Review (CSR) 1975–2018. In: Howlader N, Noone A, Krapcho M, et al., editors. SEER Cancer Statistics Review (CSR) 1975-2018. Bethesda, 2021.
4. Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer. 2019;125(14):2474–87.
5. Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836–47.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献